Case Report: Aplastic anemia related to a novel CTLA4 variant
Frontiers in Pediatrics · 16.08.2024 · 12
DOI: 10.3389/fped.2024.1434076 ↗Kurz gefasst
Fallbericht in der Zeitschrift Frontiers in Pediatrics, online erschienen am 16.08.2024. Verfasst von Geoffrey Hall und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Division of Allergy and Immunology, Duke University, Durham, NC, United States. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDDK NIH HHS, NICHD NIH HHS, NIGMS NIH HHS.
Abstract (Originalsprache)
A 20-year-old male patient with a history of celiac disease came to medical attention after developing profound fatigue and pancytopenia. Evaluation demonstrated pan-hypogammaglobulinemia. There was no history of significant clinical infections. Bone marrow biopsy confirmed hypocellular marrow consistent with aplastic anemia. Oncologic and hematologic evaluations were unremarkable for iron deficiency, paroxysmal nocturnal hemoglobinuria, myelodysplastic syndromes, T-cell clonality, and leukemia. A next generation genetic sequencing immunodeficiency panel revealed a heterozygous variant of uncertain significance in CTLA4 c.385T >A, p.Cys129Ser (C129S). Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) is an inhibitory receptor important in maintaining immunologic homeostasis. To determine the functional significance of the C129S variant, additional testing was pursued to assess for diminished protein expression, as described in other pathogenic CTLA4 variants. The results demonstrated severely impaired CTLA-4 expression and CD80 transendocytosis, consistent with other variants causing CTLA-4 haploinsufficiency. He was initially treated with IVIG and cyclosporine, and became transfusion independent for few months, but relapsed. Treatment with CTLA-4 - Ig fusion protein (abatacept) was considered, however the patient opted for definitive therapy through reduced-intensity haploidentical hematopoietic stem cell transplant, which was curative.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pediatrics, Division of Allergy and Immunology, Duke University, Durham, NC, United States.
- Department of Pathology, Microbiology and Immunology, and Vanderbilt Center for Immunobiology, Vanderbilt University Medical Center, Nashville, TN, United States.
- Department of Pediatrics, Division of Transplant and Cellular Therapy, Duke University, Durham, NC, United States.
- Department of Pediatrics, Division of Pediatric Hematology/Oncology, Duke University, Durham, NC, United States.
- Department of Pediatrics, Division of Pediatric Allergy, Immunology and Rheumatology, Johns Hopkins, Baltimore, MD, United States.
- Department of Medicine, Division of Allergy and Clinical Immunology, Johns Hopkins, Baltimore, MD, United States.
Förderung
- NIDDK NIH HHS
- NICHD NIH HHS
- NIGMS NIH HHS
- NIAID NIH HHS
Zitieren
APA
Hall, G., Markle, J. G., Maiarana, J., Martin, P. L., Rothman, J. A., Sleasman, J. W., Lederman, H., Azar, A. E., Brodsky, R. A., & Mousallem, T. (2024). Case Report: Aplastic anemia related to a novel CTLA4 variant. Frontiers in Pediatrics, 12. https://doi.org/10.3389/fped.2024.1434076
Vancouver
Hall G, Markle JG, Maiarana J, Martin PL, Rothman JA, Sleasman JW, et al. Case Report: Aplastic anemia related to a novel CTLA4 variant. Frontiers in Pediatrics. 2024;12. doi:10.3389/fped.2024.1434076
BibTeX
@article{Hall2024,
author = {Hall, Geoffrey and Markle, Janet G and Maiarana, James and Martin, Paul L and Rothman, Jennifer A and Sleasman, John W and Lederman, Howard and Azar, Antoine E and Brodsky, Robert A and Mousallem, Talal},
title = {Case Report: Aplastic anemia related to a novel CTLA4 variant},
journal = {Frontiers in Pediatrics},
year = {2024},
volume = {12},
doi = {10.3389/fped.2024.1434076}
}
EUVIMED